Bris­tol My­ers cuts PhI­II PD-1/LAG-3 tri­al in col­orec­tal can­cer short af­ter drug com­bo fails analy­sis

Bris­tol My­ers Squibb is ax­ing a Phase III tri­al in­ves­ti­gat­ing its com­bi­na­tion of nivolum­ab (Op­di­vo) and re­latlimab in col­orec­tal can­cer af­ter a da­ta mon­i­tor­ing com­mit­tee …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER